AGL 40.02 Decreased By ▼ -0.01 (-0.02%)
AIRLINK 127.99 Increased By ▲ 0.29 (0.23%)
BOP 6.66 Increased By ▲ 0.05 (0.76%)
CNERGY 4.44 Decreased By ▼ -0.16 (-3.48%)
DCL 8.75 Decreased By ▼ -0.04 (-0.46%)
DFML 41.24 Decreased By ▼ -0.34 (-0.82%)
DGKC 86.18 Increased By ▲ 0.39 (0.45%)
FCCL 32.40 Decreased By ▼ -0.09 (-0.28%)
FFBL 64.89 Increased By ▲ 0.86 (1.34%)
FFL 11.61 Increased By ▲ 1.06 (10.05%)
HUBC 112.51 Increased By ▲ 1.74 (1.57%)
HUMNL 14.75 Decreased By ▼ -0.32 (-2.12%)
KEL 5.08 Increased By ▲ 0.20 (4.1%)
KOSM 7.38 Decreased By ▼ -0.07 (-0.94%)
MLCF 40.44 Decreased By ▼ -0.08 (-0.2%)
NBP 61.00 Decreased By ▼ -0.05 (-0.08%)
OGDC 193.60 Decreased By ▼ -1.27 (-0.65%)
PAEL 26.88 Decreased By ▼ -0.63 (-2.29%)
PIBTL 7.31 Decreased By ▼ -0.50 (-6.4%)
PPL 152.25 Decreased By ▼ -0.28 (-0.18%)
PRL 26.20 Decreased By ▼ -0.38 (-1.43%)
PTC 16.11 Decreased By ▼ -0.15 (-0.92%)
SEARL 85.50 Increased By ▲ 1.36 (1.62%)
TELE 7.70 Decreased By ▼ -0.26 (-3.27%)
TOMCL 36.95 Increased By ▲ 0.35 (0.96%)
TPLP 8.77 Increased By ▲ 0.11 (1.27%)
TREET 16.80 Decreased By ▼ -0.86 (-4.87%)
TRG 62.20 Increased By ▲ 3.58 (6.11%)
UNITY 28.07 Increased By ▲ 1.21 (4.5%)
WTL 1.32 Decreased By ▼ -0.06 (-4.35%)
BR100 10,081 Increased By 80.6 (0.81%)
BR30 31,142 Increased By 139.8 (0.45%)
KSE100 94,764 Increased By 571.8 (0.61%)
KSE30 29,410 Increased By 209 (0.72%)

John Havlicek, a Hall of Famer and the Boston Celtics' all-time leading scorer, died Thursday in Florida. He was 79. Havlicek spent all 16 seasons of his NBA career with the Celtics, won eight NBA titles and was selected to the all-star team 13 times. He had been suffering from Parkinson's disease. The Celtics released a statement Thursday, describing Havlicek as "thoughtful and generous" and calling him the perfect team player.
"His defining traits as a player were his relentless hustle and wholehearted commitment to team over self," a team statement read. "John's passion and energy endeared him to basketball fans and made him a model for generations of NBA players."

Copyright Agence France-Presse, 2019

Comments

Comments are closed.